iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Sun Pharmaceutical gets "Official Action Indicated" from USFDA for Mohali facility

9 Nov 2022 , 09:19 AM

Sun Pharmaceutical Industries Limited had earlier announced regarding the USFDA inspection at the Company’s Mohali (Punjab) facility from August 03 to August 12, 2022 and issuance of Form-483 by USFDA with 6 observations.

In addition to this, the Company has received a communication from the USFDA determining the inspection classification as “Official Action Indicated” (OAI).

Further, the communication states that the USFDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved and may initiate additional actions, if any, under the current Consent Decree.

The Company continues to manufacture and distribute existing products for the US market, thereby not likely to have any material adverse impact on current business from the facility.

Sun Pharma continues to cooperate with the USFDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the Company’s remedial action.

Sun Pharma remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

At around 9:18 AM, Sun Pharmaceuticals Industries Ltd is currently trading at Rs1,034.55 per share up by Rs6.75 or 0.66% from its previous closing of Rs1,027.80 per share on the BSE.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Halol facility
  • Sun Pharmaceuticals Industries
  • Sun Pharmaceuticals Industries Ltd
  • Sun Pharmaceuticals Industries Ltd announcements
  • Sun Pharmaceuticals Industries Ltd launch
  • Sun Pharmaceuticals Industries Ltd news
  • Sun Pharmaceuticals Industries Ltd shares
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.